Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24862866 | 0.92 | CYP19A1 (0.37) | CYP19A1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL19660079 | 0.89 | CYP19A1 (0.33) | CYP19A1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL23921402 | 0.88 | KCNH2 (0.39) | CYP19A1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL20282303 | 0.86 | CNR2 (0.32) | CYP19A1KCNH2 | |
| SCHEMBL21334979 | 0.81 | CYP19A1 (0.35) | CYP19A1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL20868780 | 0.81 | CYP19A1 (0.37) | CYP19A1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL20830112 | 0.79 | CNR2 (0.33) | CYP19A1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL19261340 | 0.79 | CNR2 (0.33) | CYP19A1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL25121111 | 0.79 | CNR2 (0.33) | CYP19A1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL21419346 | 0.77 | CNR2 (0.33) | CYP19A1KCNH2LMNAAPEX1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-29 | — | — | US | disclosed |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, CACNA1E, SLC8B1 | CYP19A1 3222/4885KCNH2 107/4885LMNA 2019/4885 |
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | SOD1, MPO, TFRC | CYP19A1 4510/4885KCNH2 1845/4885LMNA 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.